CD19-Targeted NEX-T CAR T

DRUG2 trials

Sponsors

Celgene Corp.

Conditions

Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.Lupus NephritisSystemic Lupus Erythematosus

Phase 2

LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS

RecruitingCTIS2023-504201-36-00

Celgene Corp.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.

Start: 2018-12-21Target: 214Updated: 2025-10-27

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

RecruitingCTIS2024-519278-37-00

Celgene Corp.Lupus Nephritis, Systemic Lupus Erythematosus

Start: 2025-10-22Target: 35Updated: 2025-12-03